Known targets — ChEMBL curated mechanism
CDK2CDK4CDK6CHEK1PDPK1PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Ucn-01. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ known ✓ | Q04759 | 14/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 13/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 12/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 12/20 | 1.00 |
| ▸ | PRKCZ known ✓ | Q05513 | 12/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 12/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 11/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 11/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 11/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 11/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 11/20 | 1.00 |
| ▸ | CHEK1 known ✓ | O14757 | 5/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 3/20 | 1.00 |
| ▸ | PDPK1 known ✓ | O15530 | 3/20 | 0.73 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.73 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 9/20 | 1.00 |
| ▸ | PRKACG | P22612 | 8/20 | 1.00 |
| ▸ | PRKACB | P22694 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ucn-01 SCHEMBL29354706 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14217901 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14190736 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL17470230 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13169435 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL259162 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL24105650 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13170168 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL20068300 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL1551632 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-12-17 | — | — | US | disclosed |
| CN-104822380-B | The novel disubstituted aminopyridine derivative of 4,6- | 维罗斯塔蒂克斯公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-108617166-A | Protein Kinase Inhibitor Benzolactam Compounds | 大冢制药株式会社 | 2018-10-02 | — | — | CN | disclosed |
| CN-108473464-A | The isoindoline ketone inhibitors of MDM2-P53 interactions with active anticancer | 阿斯泰克斯治疗有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-108290871-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-103492376-A | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LTD | 2014-01-01 | — | — | CN | disclosed |
| CN-101808994-B | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2013-05-15 | — | — | CN | disclosed |
| CN-101808994-A | Be used for Compounds and methods for that kinases regulates with and indication | PLEXXIKON INC | 2010-08-18 | — | — | CN | disclosed |
| US-20090041835-A1 | METHOD OF INHIBITING LEAKAGE OF DRUG ENCAPSULATED IN LIPOSOMES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090041835-A1 | METHOD OF INHIBITING LEAKAGE OF DRUG ENCAPSULATED IN LIPOSOMES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041835-A1 | METHOD OF INHIBITING LEAKAGE OF DRUG ENCAPSULATED IN LIPOSOMES | LIPA, PLIN5, NPC1L1 | PRKCQ 4140/4885PRKCD 4555/4885PRKD3 4778/4885 |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | PKD1, PKD2, VHL | PRKCQ 474/4885PRKCD 148/4885PRKD3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.